SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences

Biomark Med. 2020 Jul;14(10):855-867. doi: 10.2217/bmm-2019-0564. Epub 2020 Aug 18.

Abstract

Aim: Squamous cell carcinoma antigen immune complexed with immunoglobulin M (SCCA-IgM) is a useful but not completely satisfactory biomarker of hepatocellular carcinoma (HCC). Considering its gender-specific behavior in preclinical models, we investigated gender-related differences of SCCA-IgM as a prognostic marker in HCC. Patients & methods: Two hundred and eight prospectively recruited patients treated with transarterial chemoembolization in a single tertiary care hospital were retrospectively evaluated. Correlations between SCCA-IgM levels, clinical characteristics and survival were assessed according to gender. Results: When the disease was advanced, SCCA-IgM was higher in males and lower in females. Levels below 130 AU/ml predicted a significantly longer survival in males (p = 0.007) and a shorter survival in females (p = 0.01). Conclusion: In predicting the prognosis of HCC patients, the interpretation of SCCA-IgM should consider gender as a relevant variable.

Keywords: SCCA-IgM; gender; hepatocellular carcinoma; prognosis; serpins; transarterial chemoembolization.

MeSH terms

  • Adult
  • Aged
  • Antigens, Neoplasm*
  • Biomarkers, Tumor
  • Carcinoma, Hepatocellular* / mortality
  • Carcinoma, Hepatocellular* / therapy
  • Chemoembolization, Therapeutic*
  • Female
  • Humans
  • Immunoglobulin M* / blood
  • Liver Neoplasms* / mortality
  • Liver Neoplasms* / therapy
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Serpins*
  • Sex Factors

Substances

  • squamous cell carcinoma-related antigen
  • Antigens, Neoplasm
  • Serpins
  • Immunoglobulin M
  • Biomarkers, Tumor